is found to be required for optimal anti-tumor responses of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint blockade.33 These results indicate that the microbiome can play pivotal roles in cancer immunotherapy efficacy regarding T cell immunotherapies as well as potential GVT effects post-allo-HSCT. Here, CTLA4 is linked to cancer.